Hostname: page-component-848d4c4894-cjp7w Total loading time: 0 Render date: 2024-06-30T20:17:38.907Z Has data issue: false hasContentIssue false
  • English
  • Français

958 – Efficacy Of Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-deficit/hyperactivity Disorder: Effect Of Age, Sex And Baseline Disease Severity

Published online by Cambridge University Press:  15 April 2020

M. Lecendreux ,
T. Banaschewski ,
C. Soutullo ,
M. Johnson ,
A. Zuddas ,
C. Anderson ,
R. Civil ,
N. Higgins ,
R. Bloomfield  and
L. Squires
...Show all authors
M. Lecendreux
Affiliation:
Pediatric Sleep Center, CHU Robert Debré, Paris, France
T. Banaschewski
Affiliation:
Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
C. Soutullo
Affiliation:
Child and Adolescent Psychiatry Unit, Department of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain
M. Johnson
Affiliation:
Child Neuropsychiatry Unit, Queen Silvia Children's Hospital, Gothenburg, Sweden
A. Zuddas
Affiliation:
Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy
C. Anderson
Affiliation:
Shire Development LLC, Wayne, PA, USA
R. Civil
Affiliation:
Shire Development LLC, Wayne, PA, USA
N. Higgins
Affiliation:
Shire Development LLC, Wayne, PA, USA
R. Bloomfield
Affiliation:
Shire Pharmaceutical Development Ltd, Basingstoke
L. Squires
Affiliation:
Shire Development LLC, Wayne, PA, USA
D. Coghill
Affiliation:
Division of Neuroscience, Ninewells Hospital, Dundee, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

In a European, phase 3 study (SPD489-325), lisdexamfetamine dimesylate (LDX) was more effective than placebo in improving symptoms and global functioning in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Objectives and aims

To evaluate the impact of age, sex and baseline disease severity on efficacy outcomes in SPD489- 325.

Methods

This 7-week, double-blind, parallel-group, dose-optimized study enrolled patients aged 6-17 years with ADHD. Patients were randomized (1:1:1) to once-daily LDX (30, 50 or 70mg/day), osmotic-release oral system methylphenidate (OROS-MPH; 18, 36 or 54mg/day) or placebo. Efficacy outcomes were analysed in patients dichotomized by age (6-12 years [n=229] or 13-17 years [n=88]), sex (male [n=255] or female [n=62]) and baseline ADHD Rating Scale version IV (ADHD-RSIV) total score (28-41 [n=161] or 42-54 [n=152]). Endpoint was the last on-treatment visit with a valid assessment.

Results

At endpoint, differences (active-placebo) in least-squares mean changes from baseline in ADHD-RS-IV total scores were statistically significant in all age, sex and ADHD-RS-IV total score subgroups for LDX (p< 0.001; effect sizes, 1.68-2.26) and OROS-MPH (p< 0.01; effect sizes, 0.88-1.46). Proportions of patients with a Clinical Global Impressions-Improvement rating of 1 (very much improved) or 2 (much improved) were statistically significantly greater than placebo at endpoint in all subgroups receiving LDX (p< 0.01) and in all subgroups except females receiving OROS-MPH (p< 0.05).

Conclusions

LDX showed greater efficacy than placebo in children and adolescents with ADHD, regardless of their age, sex or baseline disease severity.

Supported by: Funding from Shire Development LLC.

Type
Abstract
Information
European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E392
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.